关注
Fresia Pareja
Fresia Pareja
在 mskcc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
8152018
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
F Pareja, FC Geyer, C Marchiò, KA Burke, B Weigelt, JS Reis-Filho
NPJ breast cancer 2 (1), 1-11, 2016
1692016
The spectrum of triple-negative breast disease: high-and low-grade lesions
FC Geyer, F Pareja, B Weigelt, E Rakha, IO Ellis, SJ Schnitt, JS Reis-Filho
The American journal of pathology 187 (10), 2139-2151, 2017
1652017
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
DA Ferraro, N Gaborit, R Maron, H Cohen-Dvashi, Z Porat, F Pareja, ...
Proceedings of the National Academy of Sciences 110 (5), 1815-1820, 2013
1512013
The landscape of somatic genetic alterations in metaplastic breast carcinomas
CKY Ng, S Piscuoglio, FC Geyer, KA Burke, F Pareja, CA Eberle, RS Lim, ...
Clinical cancer research 23 (14), 3859-3870, 2017
1472017
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ...
Nature communications 9 (1), 1816, 2018
1322018
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and …
SK Mahil, N Wilson, N Dand, NJ Reynolds, CEM Griffiths, R Emsley, ...
British Journal of Dermatology 182 (5), 1158-1166, 2020
1192020
Genetic heterogeneity in therapy-naive synchronous primary breast cancers and their metastases
CKY Ng, FC Bidard, S Piscuoglio, FC Geyer, RS Lim, I de Bruijn, R Shen, ...
Clinical cancer research 23 (15), 4402-4415, 2017
1162017
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
S Chiang, B Weigelt, HC Wen, F Pareja, A Raghavendra, LG Martelotto, ...
Cancer research 76 (24), 7118-7129, 2016
1162016
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors
F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, ...
Nature Communications 9 (1), 3533, 2018
1102018
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
B Weigelt, R Bi, R Kumar, P Blecua, DL Mandelker, FC Geyer, F Pareja, ...
JNCI: Journal of the National Cancer Institute 110 (9), 1030-1034, 2018
1052018
Breast intraductal papillomas without atypia in radiologic‐pathologic concordant core‐needle biopsies: rate of upgrade to carcinoma at excision
F Pareja, AD Corben, SB Brennan, MP Murray, ZL Bowser, K Jakate, ...
Cancer 122 (18), 2819-2827, 2016
1022016
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression
F Pareja, DA Ferraro, C Rubin, H Cohen-Dvashi, F Zhang, S Aulmann, ...
Oncogene 31 (43), 4599-4608, 2012
992012
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing …
MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ...
Breast cancer research and treatment 167, 731-740, 2018
892018
Ovarian cancer mutational processes drive site-specific immune evasion
I Vázquez-García, F Uhlitz, N Ceglia, JLP Lim, M Wu, N Mohibullah, ...
Nature 612 (7941), 778-786, 2022
862022
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYBNFIB fusion gene
J Kim, FC Geyer, LG Martelotto, CKY Ng, RS Lim, P Selenica, A Li, ...
The Journal of pathology 244 (2), 143-150, 2018
862018
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD
F Pareja, D Macleod, C Shu, JF Crary, PD Canoll, AH Ross, MD Siegelin
Molecular cancer research 12 (7), 987-1001, 2014
812014
The genomic landscape of mucinous breast cancer
F Pareja, JY Lee, DN Brown, S Piscuoglio, R Gularte-Mérida, P Selenica, ...
JNCI: Journal of the National Cancer Institute 111 (7), 737-741, 2019
802019
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
N Ben-Chetrit, D Chetrit, R Russell, C Koerner, M Mancini, A Abdul-Hai, ...
Science Signaling 8 (360), ra7-ra7, 2015
692015
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases
EM da Silva, DJ Fix, APM Sebastiao, P Selenica, L Ferrando, SH Kim, ...
Modern Pathology 34 (8), 1570-1587, 2021
652021
系统目前无法执行此操作,请稍后再试。
文章 1–20